Document:

EX-10.1

   

  Exhibit 10.1

   

  Certain information marked as [****] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential.

   

  AMENDMENT #2

  TO

  SUPPLY AGREEMENT

   

   

  This Amendment #2 to Supply Agreement (“Amendment”) is made effective as of July 19, 2022 (the “Amendment Effective Date”) and entered into by and between Sight Sciences, Inc., a Delaware corporation having a principal place of business at 4040 Campbell Ave., Suite 100, Menlo Park, California 94025 (“Buyer”) and Peter’s Technology (Suzhou) CO., LTD., a Suzhou, Jiangsu Province corporation, with its principal place of business at No. 99 Jishi East Road, Wu Jiang District, Suzhou City, Jiangsu Province, P.R. China 215200 (“Supplier”).

   

  RECITALS

   

  WHEREAS, Buyer and Supplier are parties to that certain Supply Agreement, effective as of January 14, 2020 (as the same has been or may be amended, the “Agreement”); and

   

  WHEREAS, the Parties wish to amend certain of their respective rights and obligations under the Agreement as set forth herein.

   

  NOW, THEREFORE, in consideration of the covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

   

  AGREEMENT

   

  1.This Amendment shall be effective as of the Amendment Effective Date.  

   

  2.Exhibit A shall be amended in its entirety and replaced with the attached Exhibit A as of the Amendment Effective Date.

   

  3.All capitalized terms not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.

   

  4.Unless specifically amended herein, all other terms and conditions of the Agreement, including the remainder of Exhibit A, shall continue in full force and effect.

   

   

   

  

   

  The parties have caused this Agreement to be executed as of the Effective Date.

   

  		
	SIGHT SCIENCES, INC.
 
 
By /s/ Ken Gillette – Dir. Global Supply Chain
 [Name and Title] 
	  
 
 
Date July 25, 2022
 
 
 
	PETER’S TECHNOLOGY (SUZHOU) CO., LTD.
 
By /s/ Calvin Kuo
 
Calvin Kuo
(print name)
 
Title: General Manager
 
Date: July 26, 2022
 
 
 

   

   

   

   

  

   

  EXHIBIT A

   

  PRODUCTS; PRODUCT PRICING

   

   

  1.   Products; Prices.  Products and Product prices are as follows:

   

  			
	Product No.
	Product Description
	Price Per Unit

	FG-06721
	1-102 OMNI Surgical System (US)
	[****]

	FG-06722
	1-103 OMNI Surgical System (OUS)
	[****]

	FG-06011
	1-104 OMNI Plus Surgical System (US)
	[****]

	FG-06047
	1-105 OMNI Plus Surgical System (OUS)
	[****]

	FG-07938
	5-117 SmartLids, Single Pair, Gen 1.5
	[****]

	FG-08255
	1-107 Sion Surgical System
	[****]

	FG-07441
	1-108 OMNI Surgical System (US)
	[****]

	FG-07442
	1-109 OMNI Surgical System (OUS)
	[****]

   

   

  Products are current revision in accordance with Sight Sciences’ released specifications.EX-10.1

  Exhibit 10.1

   

  EXHIBIT A

   

  SEPARATION OF EMPLOYMENT AGREEMENT AND GENERAL RELEASE

   

  On December 23, 2021, SpartanNash Company and Yvonne Trupiano (the “Executive”) entered into a certain Employment Agreement, including this Exhibit A Separation of Employment Agreement and General Release.  This Agreement sets forth the terms of your separation of employment with SpartanNash Company (the “Company”). If you understand and agree with these terms, please sign in the space provided below. If you and the Company sign below, this will be a legally binding document representing the entire agreement between you and the Company regarding the subjects it covers. We will refer to this document as this “Agreement.”

   

  Termination Date. Your last day of work with the Company will be April 29, 2022.

   

  Consideration.  Subject to the Executive’s delivery and non-revocation of this Agreement, the Executive will receive the following:

   

  (a)The Company will pay the Executive an amount equal to one and one half times  the sum calculated by adding (i) the Executive’s annual Base Salary in effect immediately prior     to the date of termination plus (ii) the Executive’s target Annual Bonus for the year of termination. Payment shall be made in a lump sum payment within 60 days following the termination date.

   

  (i)Base Salary = $466,000 

  (ii)Target Annual Bonus = $279,600

  Total = $745,600 x 1.5 = $1,118,400

   

  (b)During the one and one half year period following the termination date, if the Executive timely elects continued coverage (“COBRA”) under Section 4980B of the Internal Revenue Code (the “Code”), the Company will reimburse Executive for the monthly COBRA cost of continued medical and dental coverage under the health, dental and prescription drug plans of the Company for the Executive and the Executive’s eligible dependents, less the amount  that the Executive would be required to contribute for health, dental and prescription drug coverage if the Executive were an active employee of the Company; provided that such reimbursements shall not continue beyond the first to occur of (x) the date on which the Executive fails to pay the COBRA cost of such continuation coverage or (y) the date on which the Executive is eligible for substantially similar coverage from a subsequent employer. These reimbursements will commence within 60 days following the termination date and will be paid on the first payroll date of each month, provided that the Executive demonstrates proof of payment of the applicable        premiums prior to the applicable reimbursement payment date.

   

   

  A-1

  

  Exhibit 10.1

  (c)The Company shall pay the Executive a prorated Annual Bonus for the year in which the Executive’s termination of employment occurs. The prorated Annual Bonus shall be determined by multiplying the full year Annual Bonus that would otherwise have been payable to the Executive, based upon the achievement of the applicable performance goals, as determined    by the Board, by a fraction, the numerator of which is the number of days during which the Executive was employed by the Company in the fiscal year in which the termination date occurs and the denominator of which is 365 (“Prorated Bonus”). The Prorated Bonus, if any, shall be paid at the same time as bonuses are paid to other employees of the Company, but not later than two and a half months after the end of the fiscal year in which the termination date occurs.

   

  (d)The Company shall pay any other amounts earned, accrued and owing but not yet  paid under the Employment Agreement and any benefits accrued and due under any applicable benefit plans     and programs of the Company (“Accrued Obligations”), regardless of whether the Executive executes or revokes this Agreement.

   

  (e)During the period beginning on the termination date and ending on the earlier of (i) the end of the twelfth (12) month after the termination date; or (ii) the date on which the Executive receives a substantially equal benefit from a new employer, the Company will continue the Executive’s tax and financial planning benefits offered to Executive during the Term of Executive’s employment.

   

  (f)The Company agrees that it will cover the cost of the Executive’s 2022 executive physical, which was scheduled for the month of August 2022 while Executive was an employee of Company and entitled to this benefit, provided that such physical occurs no later than December 15, 2022.  

   

  (g)The Company agrees to waive the noncompetition restrictions set forth in Section 14(a) of the Employment Agreement and Long-Term Incentive Plans. Notwithstanding anything to the contrary, Executive acknowledges, agrees, and covenants that all other restrictive covenants in Section 14 of the Employment Agreement and Long-Term Incentive Plans between Company and the Executive shall remain in effect following the Termination Date indefinitely. 

   

  Release of Claims. In exchange for the payment(s) described in the Consideration clause above, you hereby waive all claims available under federal, state or local law against the Company and the directors, officers, employees, employee benefit plans and agents of the Company arising out of your employment with the Company or the termination of that employment, including but not limited to all claims arising under the Americans with Disabilities Act, the Civil Rights Act of 1991, the Employee Retirement Income Security Act, the Equal Pay Act, the Genetic Information Non-discrimination Act, the Family and Medical Leave Act, Section 1981 of the United States Code, Title VII of the Civil Rights Act, the Age Discrimination in Employment Act and the Older Workers Benefit Protection Act, the Elliott-Larsen Civil Rights Act, Michigan Persons With Disabilities Civil Rights Act, Michigan Equal Pay Law, Michigan Whistleblower's Protection Act, Michigan Paid Medical Leave Act, Michigan Minimum Wage Law of 1964, Michigan Payment of Wages and Fringe Benefits Law, Michigan Sales Representatives Commission Act, if applicable, Michigan WARN Laws, the Bullard-Plawecki Employee Right 

   

  A-2

  

  Exhibit 10.1

  to Know Act, the Social Security Number Privacy Act, the Internet Privacy Protection Act, and Michigan Occupational Safety and Health Act, as well as wrongful termination claims, breach of contract claims, discrimination claims, harassment claims, retaliation claims, whistleblower claims (to the fullest extent they may be released under applicable law), defamation or other tort claims, and claims for attorneys’ fees and costs. You are not waiving your right to vested benefits under the written terms of the retirement plan, claims for unemployment or workers’ compensation benefits, any medical claim incurred during your employment that is payable under applicable medical plans or an employer-insured liability plan, claims arising after the date on which you sign this Agreement, or claims that are not otherwise waivable under applicable law. In addition, you are not waiving any claim relating to directors’ and officers’ liability insurance coverage or any right of indemnification under the Company’s articles of incorporation and bylaws.

   

  Non-Disparagement.  Executive agrees that she will not make any statement to any third party that is intended to or is reasonably likely to disparage, slander or otherwise damage the business reputation of the Company or any of its executives, officers, board members, or employees.  The Company will not direct or authorize any of its directors or executive officers to make any statement to any third party that is intended to or is reasonably likely to disparage, slander, or otherwise damage the business reputation of Executive.  

   

  Medicare Disclaimer. You represent that you are not a Medicare beneficiary as of the time you enter into this Agreement. To the extent that you are a Medicare beneficiary, you agree to contact a Company Human Resources Representative for further instruction.

   

  Limit on Disclosures. You shall not disclose or cause to be disclosed the terms of this Agreement to any person (other than your spouse or domestic/civil union partner, attorney and tax advisor), except pursuant to a lawful subpoena, as set forth in the Reports to Government Entities clause below or as otherwise permitted by law prior to the time the Company discloses the terms of this Agreement. This provision is not intended to restrict  your legal right to discuss the terms and conditions of your employment.

   

  Reports to Government Entities. Nothing in this Agreement, including the Limit on Disclosures or Release of Claims clause, restricts or prohibits you from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or filing a claim or assisting with an investigation directly with a self- regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General (collectively, the “Regulators”), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. However, to the maximum extent permitted by law, you are waiving your right to receive any individual monetary relief from the Company or any others covered by the Release of Claims resulting from such claims or conduct, regardless of whether you or another party has filed them, and in the event you obtain such monetary relief, the Company will be entitled to an offset for the payments made pursuant to this Agreement. This Agreement does not limit your right to receive an award from any 

   

  A-3

  

  Exhibit 10.1

  Regulator that provides awards for providing information relating to a potential violation of law. You do not need the prior authorization of the Company to engage in conduct protected by this paragraph, and you do not need to notify the Company that you have engaged in such conduct.

   

  Please take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose trade secrets to their attorneys, courts, or government officials in certain, confidential circumstances that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.

   

  Nonadmission of Liability. Nothing in this Agreement is an admission of any wrongdoing, liability or unlawful activity by you or by the Company.

   

  No Other Amounts Due. You acknowledge that the Company has paid you all wages, salaries, bonuses, benefits and other amounts earned and accrued, less applicable deductions, and that the Company has no obligation to pay any additional amounts other than the payment(s) described in the Consideration clause of this Agreement.

   

  Signature. The Company hereby advises you to consult with an attorney prior to signing this Agreement. You acknowledge that you have had a reasonable amount of time [number of days] to consider the terms of this Agreement and you sign it with the intent to be legally bound.

   

  Acknowledgment of Voluntariness and Time to Review. You acknowledge that:

   

  •you read this Agreement and you understand it;

  •you are signing this Agreement voluntarily in order to release your claims against the Company in exchange for payment that is greater than you would otherwise have received;

  •you have been offered at least 21 days to consider your choice to sign      this Agreement;

  •the Company advises you to consult with an attorney;

  •you know that you can revoke this Agreement within seven days of signing it and that the Agreement does not become effective until that seven-day period has passed. To revoke, contact Ileana McAlary, Chief Legal Officer.

  •you agree that changes to this Agreement before its execution, whether material or immaterial, do not restart your time to review this Agreement.

   

   

   

  A-4

  

  Exhibit 10.1

  SpartanNash

   

   

  Name:  Tony Sarsam	

   

  Date:	 April__, 2022	

   

   

  EXECUTIVE

   

   

   

  Name:  Yvonne Trupiano	

   

  Date:  April  , 2022	

   

  A-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]